Advanced searches left 3/3

Omeprazole - Crossref

Summarized by Plex Scholar
Last Updated: 21 June 2022

* If you want to update the article please login/register

Acceleration of Gastric Ulcer Healing by Omeprazole in Portal Hypertensive Rats

Although proton pump inhibitors are more potent anti-ulcer agents, there is no evidence regarding their use for gastric ulcer in cases of PHT. PHT significantly reduced epithelial cell proliferation and delayed gastric ulcer healing in PHT versus SO rats 14 days after ulcer induction. Following PHT rats' treatment with omeprazole, Serum gastrin levels were significantly higher in PHT rats than in SO rats. Omeprazole restored the reduced PCNA LI at the ulcer margin in PHT rats to that present in SO rats. Since gastrin is a potent stimulator of gastric epithelial cell proliferation, increased serum gastrin levels may be a contributing factor in omeprazole-induced epithelial cell proliferation and acceleration of gastric ulcer healing in PHT cases.

Source link: https://doi.org/10.1159/000069397


Evaluation of gastric pH-dependent drug interaction between famitinib and the commonly used proton pump inhibitor omeprazole in healthy subjects

Aims: To determine the potential gastric pH-dependent drug-drug interaction, safety, and tolerability of famitinib co-administered with omeprazole in healthy subjects. On day 10, omeprazole was administered as a single oral 25 mg under a fasting state, and on the follow-up 7 days later. Following each famitinib dose, blood samples were collected at predetermined timepoints for the pharmacokinetic analysis of both famotinib and its metabolite SHR116637. 0. 989, 0. 956, and 0. 953 respectively. The least-squares geometric mean ratios of C, AUC, and AUC for famitinib were calculated using omeprazole, to famitinib alone were 0. 989, 0. 956, and 0. 953, respectively. During the treatment period, 9 patients reported 16 treatment emergent adverse events, out of which 6 subjects reported 9 TEAEs and 1 subject reported 1 TEAE during famitinib or omeprazole administered alone, respectively, 5 subjects reported 6 TEAEs during the combined administration phase.

Source link: https://doi.org/10.22541/au.165547983.39471139/v1


Is Omeprazole or Misoprostol Superior for Improving Indomethacin-Induced Delayed Maturation of Granulation Tissue in Rat Gastric Ulcers?

Background and Aims: Proton pump inhibitors and prostaglandin tablets are said to both prevent NSAID-induced gastric ulcer formation and expedite ulcer healing by NSAIDs, but it is unknown which of these medications is the best. Methods: We used acetic acid to cause gastric ulcers in rats, and we compared the change between a control group, NSAID group, NSAID + PPI group, and the NSAID + PG group in rats. An ulcer index was established after removing the stomach of each animal, and the collagen content and type III collagen of granulation tissue were determined. Omeprazole promoted epithelialization, but it was unable to completely reverse the effects of indomethacin on granulation tissue maturation. Conclusions: From our point of view in this research on the use of experimental ulcers, it was thought that PG compensation should take precedence over gastric acid inhibition in terms of ulcer repair.

Source link: https://doi.org/10.1159/000092012


Omeprazole for Peptic Ulcer Disease in Pregnancy

This paper includes the findings of nine women who received omeprazole for severe reflux disease during different stages of pregnancy. At the time of birth, three of these patients received omeprazole, and three of them continued omeprazole therapy without interruption until delivery. In the other 3 patients, the rest of the patients began therapy in weeks 24, 30, 33, 34, and 36 of pregnancy due to bleeding in two patients and uncommonable H2 receptor refractory reflux symptoms.

Source link: https://doi.org/10.1159/000007570


Comparison of Omeprazole, Metronidazole and Clarithromycin with Omeprazole/Amoxicillin Dual-Therapy for the Cure of Helicobacter pylori Infection

Patients with duodenal ulcers were randomly selected either omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg given three times daily for ten days, or a combination of omeprazole 20 mg and amoxicillin 1 g given twice daily for 14 days. In the per-protocol test, OCM and in 68% following OA were cured in 97. 4% and in 65. 8%. In 122 patients, H. pylori was successfully cultured. All patients infected with metronidazole-sensitive H. pylori strains and those infected with bacteria of unknown susceptibility to metronidazole were cured, while 77% of those harboring metronidazole-resistant strains were cured of the disease. In 2. 5 percent of the patients in the OCM group and in 1. 4% of the OA group, side effects leading to early termination of therapy were present in 2. 5 percent of the patients and in 1. 4% of the OA group.

Source link: https://doi.org/10.1159/000007569


Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer Patients

The aim of the current review was to determine the effectiveness of omeprazole-based dual and triple therapy regimens, both including clarithromycin, for the treatment of H. pylori infection in active GU and duodenal ulcer patients. Methods: Two hundred and thirty-four peptic ulcer patients suffering from H. pylori infection were randomly treated with omeprazole 20 mg b. i. d. H. pylori infection in GU patients was 83. 9% with OAC and 592 with OC, with 58. 2% with OC. Conclusions: omeprazole, amoxicillin, and clarithromycin are a safe and effective treatment for H. pylori infection in GU patients as well as in DU patients. In Japan, we recommend this triple regimen as a first-line therapy in all patients with peptic ulcers associated with H. pylori infection.

Source link: https://doi.org/10.1159/000007509


Increased Hepatocyte Growth Factor Content in Rat Stomach during Omeprazole Treatment

Hepatocyte growth factor is a potent epithelial cell precursor, and its production is stimulated during gastric mucosal lesions healing. In the rat stomach, HGF gene expression and the amount of HGF were investigated. Although omeprazole treatment did not improve the indomethacin-induced rise in HGF gene expression, it did not significantly raise the gastric HGF content. Also, omeprazole raised the gastric content not only of the inactive but also of the active heterodimeric form of HGF, which seemed to be due to the inhibition of the HGF degradation by gastric juice.

Source link: https://doi.org/10.1159/000007474


Influence of Helicobacter pylori Infection and Omeprazole Treatment on Gastric Regional CO 2

H. pylori -positive over H. pylori -negative subjects before but not after the use of omeprazole. In H. pylori-positive animals, the effect of omeprazole on gastric juice pH was raised. Between H. pylori - positive and H. pylori - negative subjects There was a difference in arterial pCO2 between H. pylori - positive and H. pylori - negative subjects. Conclusion: The use of a proton pump inhibitor reduces H. pylori infection in gastric regional CO 2 that is reduced by the use of a proton pump inhibitor.

Source link: https://doi.org/10.1159/000072056


Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux Esophagitis

Aim: To determine the efficacy and tolerability of pantoprazole 40 mg and omeprazole 40 mg in patients with moderate to severe gastroesophageal reflux disease. In addition, the investigator used a questionnaire assessing heartburn, reflux regurgitation, and pain on swallowing at each visit, as well as a self-administered questionnaire containing further 24 gastrointestinal symptoms. 552 patients, 282 treated with pantoprazole, and 270 with omeprazole MUPS were treated in the PP population. In addition, patients infected with H. pylori had marginally higher healing rates than those with negative test results. After 4 and 8 weeks of treatment in patients with reflux esophagitis grade II/III, Pantoprazole 40 mg and omeprazole 40 mg were essentially equivalent in terms of recovery. Overall, HC patients had higher healing rates than those who were not.

Source link: https://doi.org/10.1159/000070201


Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer

Compared to omeprazole 40 mg, it was to determine the efficacy of rabeprazole at 20 and 40 mg in comparison to amoxicillin and clarithromycin in the therapy of active Helicobacter pylori -positive duodenal ulcers in infants. Patients and Methods: Patients and Methods: One hundred and twenty-seven patients were randomly divided into three therapeutic groups: 40 patients were treated with rabeprazole 40 mg daily, 42 patients were treated with rabeprazole 20 mg daily, and 45 patients were treated with omeprazole 40 mg daily for ten days, and 45 patients were treated with omeprazole 40 mg daily. In 90 percent of patients in the rabeprazole 40 group and 93 percent in the omeprazole 40 group, according to the intention-to-treat protocol, ulcer healing was evident in 90% of patients in the rabeprazole 40 group and 93 percent in the omeprazole 40 group, and 93 percent in the omeprazole 40 group, with 96 percent in 93 percent. In 90 percent ITT in the rabeprazole 40 group and 88. 8% ITT in the omeprazole 40 group, we observed H. pylori eradication in 90% ITT and 88. 8% ITT in the omeprazole 40 group.

Source link: https://doi.org/10.1159/000066756

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions